Eyenexo LLC
Capital Timeline
Capital this company has received, each line traceable to a primary record. Amounts are obligations, not contract ceilings.
A blank stage means the data is not ingested yet, not that the money stopped there.
Across the lifetime of these contracts, $245K has been obligated and $182K paid out. $63K has not been disbursed.
Cumulative from contract start through 2026-08-17. The total above covers only the transactions ingested in the tracking window — a different measure.
- National Institutes of Health$01
Why It Matters
Not enough signal yet to assess this company's relevance to Japanese firms.
Events
Events used as evidence for Stage / LCI. Facts and interpretation are recorded separately.
EYENEXO LLC — Grant R43AG090213
COMPUTER VISION POWERED AUTOMATION OF RODENT ARENA FOR ASSESSMENT OF EARLY ALZHEIMER'S DISEASE. - PROJECT SUMMARY ALZHEIMER'S DISEASE (AD) IS THE MOST COMMON CAUSE OF AGE-RELATED NEURODEGENERATIVE DISEASE AND DEMENTIA. DESPITE ITS PREVALENCE AND DELIBERATING HEALTH CONSEQUENCE, EARLY DIAGNOSIS OF AD IS A SERIOUS UNMET NEED. THE CURRENT PROPOSAL SEEKS TO DEVELOP A BEHAVIOR BIOMARKER THAT DIFFERENTIATES AD FROM A NORMAL AGEING PROCESS. THE PROJECT PROPOSES TO DEVELOP AN AUTOMATED RODENT BEHAVIOR TESTING SYSTEM FOR NON-INVASIVELY ASSESSING THE EARLY AD, BASED ON STRONG EVIDENCE FROM AD IMAGING STUDIES AND NEUROPHYSIOLOGY RESEARCH ON A SPECIFIC TYPE OF INNATE DEFENSIVE BEHAVIOR ACROSS A VARIETY OF SPECIES. THE MIDBRAIN STRUCTURE GOVERNING THE SENSORIMOTOR COMPUTATION OF LOOMING STIMULI CAN TRIGGER DEFENSIVE BEHAVIORS, SUCH AS FREEZING AND ESCAPE, IN RODENTS. INTERESTINGLY, A NUMBER OF CLINICAL STUDIES HAVE SHOWN THAT THE MIDBRAIN REGION IS AFFECTED VERY EARLY IN AD. TAKING THE FINDINGS FRO
Timeline
No timeline articles for this company yet.